Biogen Inc. — stock technical analysis, week 11 of the buy signal
Biogen slips 1.8% in earnings week as the buy signal cools near the highs
Biogen Inc. — stock technical analysis, week 11 of the buy signal
Our view last week
Biogen shares, weekly technical analysis: the stock added 3.4% this week, confirming the double bottom in the 189 area with an 18% rebound. But the push is losing its shine: buyer dominance is fading and daily volume still favors sellers. Price is now boxed in a tight corridor between support and resistance, with earnings two weeks out adding weight to the timing.
This week's summary
Biogen eases back in the 190 area, down 1.8% this week heading straight into the July 29 earnings report. June's double bottom still holds and the rebound stays at 18%, but the technical picture is losing steam: weekly ADX is fading, MACD is deteriorating, and daily buyers keep the edge without really pushing. The stock is now boxed between the 20-day average and the daily VWMA, with the earnings event weighing on the timing of any fresh move.
IQS Phase
58
ordinary
Signal Strength
59
medium
Sizing
STANDARD
Ranking
#50 / 124
US stocks in progress
Trade P&L %
+4.52%
from signal to today
Rank position
ranks 50th among the 124 Longs already running for US stocks in our ranking, with a signal strength of 59 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly +0.92% · monthly +6.01%
BIIB belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content